Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2024-04-29 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 98% confidence The document is titled as the "2023 Annual Report Summary" of 广州市香雪制药股份有限公司, indicating it is a summary of the full annual report. It contains detailed financial data for the year 2023, including audited financial statements, accounting policy changes, quarterly financial data, shareholder information, and important company matters such as acquisitions and legal proceedings. The presence of comprehensive financial figures, audit opinions, and detailed business descriptions confirms this is a full annual report document rather than a brief announcement or a presentation. The document length (8713 characters) is sufficient to contain substantive financial data and analysis. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-29 Chinese
关于延期披露会计差错更正专项鉴证报告的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (691 characters) from a company about the delay in disclosing a special verification report on accounting error corrections. It references the need to issue a special verification report by an accounting firm but does not contain the report itself or detailed financial data. It is a notice about the timing of a report disclosure, not the report itself. According to the 'Menu vs Meal' rule, such announcements are classified as Report Publication Announcements (RPA).
2024-04-29 Chinese
关于申请借款重组展期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for loan restructuring and extension, including details about guarantees and collateral. It describes the approval process by the board and the impact on the company. There are no financial statements, quarterly or annual results, or detailed financial data presented. The document is relatively short (1660 characters) and serves as a disclosure of financing activity and related guarantees. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-04-29 Chinese
关于公司2023年度计提资产减值准备的公告
Audit Report / Information Classification · 95% confidence The document is an announcement by Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's 2023 annual asset impairment provision. It details the amounts of impairment provisions for various asset categories, the approval process by the board and supervisory committee, and the impact on the company's 2023 profit. The document references accounting standards and audit confirmation by an accounting firm. It is a detailed disclosure about asset impairment provisions for the fiscal year 2023, including financial figures and accounting policies. This is not a full annual report but a specific financial announcement related to asset impairment provisions. It is not a certification, call transcript, or management change announcement. Given the detailed financial data and accounting treatment, it fits best under Audit Report / Information (AR), which covers standalone audit reports and accounting principle applications excluding full annual reports. The document length (7824 characters) and content confirm it is a substantive report, not merely an announcement of a report publication or a short notice. Therefore, the classification is AR with high confidence. FY 2023
2024-04-29 Chinese
董事会关于2023年度保留意见审计报告涉及事项的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed explanation by the board of directors regarding a qualified audit opinion (保留意见审计报告) issued by the external auditor for the company's 2023 annual financial report. It discusses the audit issues, their impact on financial statements, and the board's and audit committee's opinions and planned corrective measures. The document references the 2023 annual audit and financial statements but does not contain the full annual report or the audit report itself. It is a standalone explanation related to the audit report, which fits the category of Audit Report / Information (AR). The document length is 2094 characters, which is short but contains substantive content about the audit opinion and related matters, not merely an announcement or certification. Therefore, it is classified as AR with high confidence. FY 2023
2024-04-29 Chinese
关于2023年度日常关联交易及2024年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the company's related party transactions for the year 2023 and the expected related party transactions for 2024. It includes detailed descriptions of the transactions, related parties, their relationships, and opinions from the independent directors and supervisory board. The document is an announcement of ongoing and expected related party transactions, which is a regulatory disclosure typically required by stock exchanges to inform shareholders and the market about related party dealings. It is not a financial report, audit report, or management discussion, nor is it a voting result or a meeting presentation. The document length is about 3,049 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement about related party transactions that does not fit into more specific categories like Annual Report or Interim Report.
2024-04-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.